Share on StockTwits

Synthetic Biologics (NYSE:SYN) announced its earnings results on Thursday. The company reported ($0.07) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.08) by $0.01, American Banking News reports.

On a related note, analysts at Maxim Group raised their price target on shares of Synthetic Biologics from $3.00 to $6.00 in a research note on Wednesday, March 19th. They now have a “buy” rating on the stock.

Synthetic Biologics (NYSE:SYN) opened at 1.16 on Thursday. Synthetic Biologics has a 1-year low of $0.95 and a 1-year high of $3.64. The stock’s 50-day moving average is $2.18 and its 200-day moving average is $1.9. The company’s market cap is $67.6 million.

Synthetic Biologics, Inc, formerly Adeona Pharmaceuticals, Inc, is a biotechnology company focused on the development of synthetic deoxyribonucleic acid (NYSE:SYN)-based therapeutics and disease-modifying medicines for serious illnesses.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.